Clinical Trials
14 trialsNCT02875223 2025-04-20
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Celgene
Phase 1 Terminated
NCT04537715 2025-02-19
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
Phase 1 Completed
NCT03994211 2024-10-26
Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer
BeiGene
Phase 1 Completed
NCT00585195 2023-02-08
PROFILE 1001
Pfizer
Phase 1 Completed
NCT03486314 2022-04-18
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT02197247 2021-07-12
Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC
AstraZeneca
Phase 1 Completed
NCT03077607 2021-06-30
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00207090 2020-11-02
Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer
R-Pharm
Phase 1 Completed
NCT01324323 2019-11-25
Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Celgene
Phase 1 Completed
NCT01844583 2019-03-25
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
Takeda
Phase 1 Completed
NCT01454076 2017-11-01
Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma
Takeda
Phase 1 Completed
NCT01765543 2016-12-15
A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
Hoffmann-La Roche
Phase 1 Completed
NCT01950364 2016-05-11
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT00608907 2012-01-30
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
Millennium Pharmaceuticals, Inc.
Phase 1 Completed